Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation

Bone Marrow Transplantation volume 23, pages 183–185 (1999)Cite this article

Abstract

Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    H Nagayama, S Takahashi, T Takahashi, A Tojo, K Tani & S Asano

  2. Department of Transfusion Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    K Ogami & K Ikebuchi

Authors
  1. H Nagayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Ogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Ikebuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Tojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Tani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagayama, H., Takahashi, S., Takahashi, T. et al. IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation. Bone Marrow Transplant 23, 183–185 (1999). https://doi.org/10.1038/sj.bmt.1701550

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1701550

Keywords

This article is cited by

Search

Advanced search

Quick links